These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24402090)

  • 1. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
    Meijers B; Maas RJ; Sprangers B; Claes K; Poesen R; Bammens B; Naesens M; Deegens JK; Dietrich R; Storr M; Wetzels JF; Evenepoel P; Kuypers D
    Kidney Int; 2014 Mar; 85(3):636-40. PubMed ID: 24402090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
    Sinha A; Bajpai J; Saini S; Bhatia D; Gupta A; Puraswani M; Dinda AK; Agarwal SK; Sopory S; Pandey RM; Hari P; Bagga A
    Kidney Int; 2014 Mar; 85(3):649-58. PubMed ID: 24429405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].
    Segarra A; Jatem E; Quiles MT; Arbós MA; Ostos H; Valtierra N; Carnicer C; Salcedo MT
    Nefrologia; 2014; 34(1):53-61. PubMed ID: 24463863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.
    Guo SM; Han M; Chen MX; Ning Y; Pei GC; Li YQ; Dai W; Ge SW; Deng YJ; Guo YY; Li XQ; Haller H; Xu G; Rong S
    PLoS One; 2015; 10(9):e0138718. PubMed ID: 26380984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.
    Bock ME; Price HE; Gallon L; Langman CB
    Clin J Am Soc Nephrol; 2013 Aug; 8(8):1304-11. PubMed ID: 23620441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
    Jin J; Li YW; He Q
    Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
    Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
    Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
    Schlöndorff D
    Kidney Int; 2014 Mar; 85(3):499-501. PubMed ID: 24583981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
    Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
    Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
    Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
    Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis.
    Shuai T; Pei Jing Y; Huang Q; Xiong H; Liu J; Zhu L; Yang K; Jian L
    BMJ Open; 2019 Oct; 9(10):e031812. PubMed ID: 31594897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome].
    Segarra A; Jatem E; Quiles MT; Arbós MA; Ostos H; Valtierra N; Carnicer C; Agraz I; Salcedo MT
    Nefrologia; 2014; 34(1):46-52. PubMed ID: 24463862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence.
    Mujtaba MA; Sharfuddin AA; Book BL; Goggins WC; Khalil AA; Mishler DP; Fridell JA; Yaqub MS; Taber TE
    Clin Transplant; 2015 Jul; 29(7):606-11. PubMed ID: 25973696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis.
    Sołtysiak J; Zachwieja J; Benedyk A; Lewandowska-Stachowiak M; Nowicki M; Ostalska-Nowicka D
    Minerva Pediatr; 2019 Feb; 71(1):4-11. PubMed ID: 27070416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.
    Musetti C; Quaglia M; Cena T; Chiocchetti A; Monti S; Clemente N; Magnani C; Dianzani U; Stratta P
    J Nephrol; 2015 Jun; 28(3):299-305. PubMed ID: 25185729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
    Harita Y; Ishizuka K; Tanego A; Sugawara N; Chikamoto H; Akioka Y; Tsurumi H; Miura K; Gotoh Y; Tsujita M; Yamamoto T; Horike K; Takeda A; Oka A; Igarashi T; Hattori M
    Pediatr Nephrol; 2014 Sep; 29(9):1553-60. PubMed ID: 24705794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.
    Wada T; Nangaku M; Maruyama S; Imai E; Shoji K; Kato S; Endo T; Muso E; Kamata K; Yokoyama H; Fujimoto K; Obata Y; Nishino T; Kato H; Uchida S; Sasatomi Y; Saito T; Matsuo S
    Kidney Int; 2014 Mar; 85(3):641-8. PubMed ID: 24429394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
    Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.